[{"section_title": "Abstract", "text": "For a two-sample comparison of means, the required sample size is proportional to:\nwhere Var(X 1 ) and Var(X 0 ) denote the variance of the outcome measure in the treated and untreated groups respectively, and is the difference in mean outcome between treatment groups. Let X low , X high , and X all , denote the outcome in low-A\u2424 level subjects, high-A\u2424 level subjects, and all MCI subjects respectively. Further, let low and all denote the assumed treatment effects (difference in means) in a trial recruiting only low A\u2424-MCIs and all MCIs respectively. 1 Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.ucla.edu/). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.ucla.edu/wpcontent/uploads/how to apply/ADNI Acknowledgement List. We now derive the ratio of required sample sizes for a low-A\u2424 targeted trial to the sample size for an all MCI trial, according to three alternative assumptions regarding the effect of a putative treatment: a) if treatment reduces the mean outcome proportionately by 100k% in the low-A\u2424 and by 100k% in the high-A\u2424, i.e., low = kX low and all = kX all , the ratio is:\nif treatment reduces mean outcome by an amount kX low , irrespective of whether A\u2424 is high or low, i.e. low = kX low and all = kX low , the ratio is:\nc) if treatment benefits low-A\u2424 subjects only (by reducing mean outcome by kX low ) but not high-A\u2424 subjects, i.e., low = kX low and all = pkX low , where p denotes the proportion of low-A\u2424 subjects, the ratio is:"}, {"section_title": "", "text": "For a two-sample comparison of means, the required sample size is proportional to:\nwhere Var(X 1 ) and Var(X 0 ) denote the variance of the outcome measure in the treated and untreated groups respectively, and is the difference in mean outcome between treatment groups. Let X low , X high , and X all , denote the outcome in low-A\u2424 level subjects, high-A\u2424 level subjects, and all MCI subjects respectively. Further, let low and all denote the assumed treatment effects (difference in means) in a trial recruiting only low A\u2424-MCIs and all MCIs respectively. 1 Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.ucla.edu/). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.ucla.edu/wpcontent/uploads/how to apply/ADNI Acknowledgement List. We now derive the ratio of required sample sizes for a low-A\u2424 targeted trial to the sample size for an all MCI trial, according to three alternative assumptions regarding the effect of a putative treatment: a) if treatment reduces the mean outcome proportionately by 100k% in the low-A\u2424 and by 100k% in the high-A\u2424, i.e., low = kX low and all = kX all , the ratio is:\nif treatment reduces mean outcome by an amount kX low , irrespective of whether A\u2424 is high or low, i.e. low = kX low and all = kX low , the ratio is:\nc) if treatment benefits low-A\u2424 subjects only (by reducing mean outcome by kX low ) but not high-A\u2424 subjects, i.e., low = kX low and all = pkX low , where p denotes the proportion of low-A\u2424 subjects, the ratio is:\nThis ratio is always less than p, but unlike in scenarios a) and b), the ratio depends on k. However, for small k (i.e., small treatment effects) it is approximately equal to: and hence again is independent of k."}]